CIK 0001842295
- Non-accelerated filer
- Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 650-850-5070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- 4 Planned sale President, R&D & CMO sold 4,844 shares at an average $40.39 ($195,668)
- 4 Planned sale SVP, Finance sold 5,000 shares at an average $39.15 ($195,754)
- 4 Planned sale CSBO sold 72,500 shares at an average $40.56 ($2,940,799)
- 4 Planned sale President, R&D & CMO sold 45,000 shares at an average $40.56 ($1,825,355)
- 4 Planned sale SVP, Finance sold 15,000 shares at an average $40.41 ($606,173)
- 4 Other acquisition Director acquired 1,489 shares (other)
- 4 Other disposition 10% owner disposed of 1,600,000 shares (other)
- 4 Gift Director gave 28,423 shares (gift)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 4 of 6 · 108 filings